Klaviyo's Edward Hallen plans sale of 1,300 shares
The notice separates the planned shares between Hodgkins LLC and Hodgkins Trust and includes each entity’s sales during the prior three months.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Klaviyo, Inc. (KVYO) is the issuer named in a Form 144 notice identifying Edward W. Hallen as the person for whose account 1,300 Class A shares are to be sold, with an aggregate market value of $22,124.00 and an approximate sale date of September 24, 2026. The notice attributes 800 shares to Hodgkins LLC and 500 to Hodgkins Trust; Hallen is identified as an account stakeholder in both. Past-three-month sales dated August 31, 2026, list 59,615 shares ($1,221,349.02) for the LLC and 39,167 shares ($801,622.32) for the trust. Daniel Tucci signed as Fidelity Brokerage Services LLC’s authorized representative and Hallen’s attorney-in-fact.
Key Figures
Key Terms
Rule 144 regulatory
attorney-in-fact regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Hodgkins LLC and Hodgkins Trust sell in the prior three months?
AI-generated analysis. How Rhea-AI works. Not financial advice.